• LAST PRICE
    2.2800
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.5200/ 1
  • Ask / Lots
    2.6800/ 1
  • Open / Previous Close
    0.0000 / 2.2800
  • Day Range
    ---
  • 52 Week Range
    Low 1.1500
    High 13.5100
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 2.43
TimeVolumeSERA
10:30 ET1002.4
11:26 ET19002.4
12:39 ET1312.4
01:10 ET2002.44
02:13 ET1002.36
02:47 ET3172.395
03:41 ET8332.31
03:43 ET8002.27
03:45 ET1002.25
03:59 ET3752.28
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSERA
Sera Prognostics Inc
70.5M
-1.7x
---
United StatesLTBR
Lightbridge Corp
73.7M
-2.4x
---
United StatesBCRD
Blueone Card Inc
87.4M
-159.1x
---
United StatesSBIG
springbig Holdings Inc
43.5M
6.6x
---
United StatesKICK
Master Glazier's Karate International Inc
46.6M
0.0x
---
United StatesROKK
Rokk3r Inc
54.5M
-0.1x
---
As of 2022-08-08

Company Information

Sera Prognostics, Inc. is a women’s health diagnostic company that is focused on utilizing its proteomics and bioinformatics platform to discover, develop and commercialize clinically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. The Company's commercial product, the PreTRM test, is a blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation. Its biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth and postpartum depression.

Contact Information

Headquarters
2749 E. Parleys Way, Suite 200SALT LAKE CITY, UT, United States 84109
Phone
801-505-0278
Fax
302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer
Gregory Critchfield
Chief Financial Officer
Jay Moyes
Chief Information Officer
Robert Harrison
Chief Scientific Officer
Jay Boniface
General Counsel
Benjamin Jackson

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$70.5M
Revenue (TTM)
$107.0K
Shares Outstanding
30.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.34
Book Value
$4.50
P/E Ratio
-1.7x
Price/Sales (TTM)
659.2
Price/Cash Flow (TTM)
---
Operating Margin
-37,962.62%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.